Story
AstraZeneca's Tezspire Meets Late-Stage Trial Goals for Eosinophilic Esophagitis

AstraZeneca and its partner Amgen announced Thursday that their drug Tezspire met all primary and secondary endpoints in a late-stage trial for treating eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. The positive results could pave the way for a significant new market for the drug, which is currently approved for severe asthma.
Trial Meets Key Endpoints
According to the company's statement, the study demonstrated that Tezspire was superior to a placebo in reducing esophageal inflammation, achieving its primary endpoint. The drug also successfully met its secondary endpoints, showing a notable improvement in the difficulty of swallowing (dysphagia) for patients in the trial.
Eosinophilic esophagitis is a chronic, immune-mediated disease characterized by a type of white blood cell, the eosinophil, that builds up in the esophagus. This buildup can cause inflammation, leading to difficulty eating and other complications.
Market and Pipeline Implications
AdThis successful trial is a crucial step for AstraZeneca (LON:AZN) and Amgen (NASDAQ:AMGN) as they seek to expand the approved uses for Tezspire. A new indication for EoE would broaden the drug's commercial potential beyond the competitive severe asthma market, opening up a new revenue stream.
Expanding the applications of existing drugs is a key strategy for pharmaceutical firms to maximize the value of their assets. These results strengthen the clinical profile of Tezspire as a treatment for a range of diseases driven by underlying inflammation.
About Tezspire's Mechanism
Tezspire is a monoclonal antibody that works by targeting and blocking thymic stromal lymphopoietin (TSLP), a key protein that sits at the top of multiple inflammatory cascades. By inhibiting TSLP, Tezspire can help prevent the inflammation associated with conditions like severe asthma and, as suggested by this trial, eosinophilic esophagitis.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.